Global complement inhibitors market to reach $32.40bn by 2034

9 articles · Updated · Fortune Business Insights · May 4

The market is valued at $9.00bn in 2025 and forecast to grow to $10.30bn in 2026, with a 15.40% annual growth rate through 2034.
Growth is tied to approvals expanding beyond rare blood disorders into kidney, neurology and other immune-mediated diseases, widening patient pools and supporting adoption of C5, C3, Factor B and Factor D therapies.
North America leads, with a $5.08bn market in 2025, while high therapy costs, reimbursement pressure and regulatory compliance challenges may limit broader access despite strong pipeline development.

As new immune drugs promise cures, are their soaring prices creating a new class of untreatable patients?

With a flood of new drugs, how do we prevent a 'miracle' cure from becoming a mistargeted failure?